single5MG
Retatrutide
5MG Protocol
Retatrutide 5MG
Injection Freq.
Inject once weekly
Cycle Sched.
Minimum 24 weeks; trials extended to 48 weeks
Reconstitution
1.0 mL BAC water
Exceptional weight loss reported in trials (~22–24% mean at 48 weeks at higher doses)
HbA1c reduction (~1.3–2.0%) with high rates reaching HbA1c ≤6.5%
Reduced blood pressure, LDL, waist circumference
liver-fat reduction signals
Universal ≥5% responder rate reported at higher doses
1
Reconstitution Requirements
- 1.0 mL BAC water
Escalation steps: 4
Defined through week 12
| Step | Week Range | Dose | Units |
|---|---|---|---|
| 1 | Weeks 1–4 | 2 mg (2000 mcg) | 40 |
| 2 | Weeks 5–8 | 4 mg (4000 mcg) | 80 |
| 3 | Weeks 9–12 | 6 mg (6000 mcg) | 120 |
| 4 | Weeks 1+ | 8 mg (8000 mcg) | 160 |
Inject once weekly
Minimum 24 weeks; trials extended to 48 weeks
Retatrutide (retatrutide) is described as a triple agonist that activates GLP-1, GIP, and glucagon receptors in a single weekly molecule. The protocol explains that GLP-1 activity reduces appetite and slows gastric emptying, lowering intake and smoothing post-meal glucose dynamics. GIP activity enhances glucose-dependent insulin secretion and may contribute to fat-metabolism effects. The added glucagon receptor agonism is described as increasing metabolic rate and energy expenditure, promoting fat oxidation and helping offset the adaptive metabolic slowdown that often accompanies weight loss. A fatty-acid modification extends the half-life to roughly 6 days, supporting weekly dosing. Clinical trial results summarized on the page report unusually large average weight loss at higher weekly doses along with meaningful HbA1c reductions in type 2 diabetes cohorts and improvements in cardiometabolic markers. As with other incretin-based therapies, the primary tolerability issue described is transient, dose-dependent GI symptoms during escalation.
Nausea
Vomiting
Diarrhea
Dose-dependent, transient GI symptoms (most common during escalation)
No severe hypoglycemia or serious treatment-related adverse events reported in cited trials
- Use aseptic technique: wipe vial stopper with alcohol; use new sterile syringe/needle
- Add diluent slowly down the vial wall to minimize foaming
- Gently swirl/roll until fully dissolved (do not shake)
- Label vial with reconstitution date and concentration; protect from light
- Refrigerate after reconstitution (commonly 2–8 °C) unless protocol states otherwise
- Avoid repeated freeze–thaw cycles
- Bacteriostatic Water for Injection contains benzyl alcohol preservative (multi-dose); follow protocol for beyond-use (many peptide protocols use ~28 days after mixing)
- Avoid benzyl-alcohol-containing diluents in neonates/infants (safety warning for benzyl alcohol)